Comparison of preoperative endometrial biopsy grade and final pathologic diagnosis in patients with endometrioid endometrial cancer

**Endometrioid endometriyum kanserli olgularda preoperatif endometriyal biyopsi grade ile postoperatif patolojik değerlendirme karşılaştırılması**

Behiye Pınar Çilesiz Göksedef¹, Özgür Akbayır², Aytül Çorbacıoğlu², Hakan Güraskan³, Fatmağül Şencan³, Onur Erol³, Ahmet Çetin¹

¹Department of Gynecology and Obstetrics, Haseki Teaching and Research Hospital, İstanbul, Turkey
²Department of Gynecology and Obstetrics, Istanbul Kanuni Sultan Süleyman Research and Teaching Hospital, İstanbul, Turkey
³Department of Gynecology and Obstetrics, Antalya Teaching and Research Hospital, Antalya, Turkey

**Abstract**

**Objective:** To compare preoperative grading in endometrioid endometrial cancer with the final pathologic assessment of the hysterectomy specimen. The second objective of the study was to determine a high risk group who will be upgraded in the postoperative evaluation.

**Material and Methods:** A total of 335 patients with endometrioid endometrial cancer were retrospectively reviewed between June 2000 and January 2011. All pathology results were pre- and postoperatively reviewed at two institutions, and all patients underwent surgical therapy. Sensitivity, specificity, positive and negative predictive values and accuracy rates were calculated for all grades in the preoperative assessment.

**Results:** The mean age of the patients was 56.2±9.6 and the vast majority of the patients were postmenopausal (n=239, 71.3%). FIGO grade was determined to be greater in 75 patients in the final hysterectomy specimen. Fifty-five (32.9%) of the patients with preoperative grade 1 were found to be grade 2 and 3.6% of them were upgraded to grade 3. Fourteen of the patients with grade 2 (11.4%) were found to be grade 3. Seventy-five patients with grade 2 (11.4%) were found to be grade 3. The accuracy rates of the preoperative grade assessment with endometrial sampling were 75.5%, 66.2% and 88.3% for grades 1, 2 and 3, respectively. There were no statistically significant differences in the preoperative demographic characteristics between patients with or without upgraded tumors.

**Conclusion:** A high percentage of preoperatively diagnosed grade 1 tumors were upgraded in the postoperative evaluation. The patients who would have been upgraded after hysterectomy could not have been predicted preoperatively using the characteristic features.

(J Turkish-German Gynecol Assoc 2012; 13: 106-10)

**Key words:** Endometrial cancer, biopsy, grade, preoperative evaluation, postoperative evaluation

**Received:** 15 January, 2012  **Accepted:** 22 March, 2012

**Introduction**

The grade of a tumor is a well-known prognostic factor for women with endometrial carcinoma and correlates with the depth of myometrial invasion, lymph node involvement, surgical stage and survival (1, 2). The staging for endometrial carcinoma has been suggested as a surgical-pathologic system which includes peritoneal cytology, pelvic and paraaortic lymphadenectomy (3). In 2005, the American College of Obstetricians and Gynecologists (ACOG) recommended surgical staging for women with endometrial cancer, except for young or perimenopausal women with grade 1 endo-

**Original Investigation**

106

©Copyright 2012 by the Turkish-German Gynecological Education and Research Foundation - Available online at www.jtgga.org
doi:10.5152/jtgga.2012.12
metrioid adenocarcinomas, as well as atypical endometrial hyperplasia, and women at high risk of mortality secondary to comorbidities (4). The role of lymphadenectomy has not been clearly defined in the management of endometrial cancer, especially in patients with grade 1 and 2 disease that is limited in the uterus. Some authors advise performing a routine pelvic and/or para-aortic lymphadenectomy in all women (5), whereas others have questioned the clinical utility of this procedure because of the complications of lymphadenectomy, especially in patients at low risk of nodal involvement (grade 1 or 2 with no or minimal myometrial invasion) (6, 7).

Approximately 52% of women with endometrioid carcinoma have a preoperative endometrial biopsy showing grade 1 (8). The accuracy of preoperative grading is an extremely important issue in young patients with well-differentiated endometrial carcinoma who desire future fertility and uterine preservation. In addition, preoperative endometrial biopsy is often the basis of referral to centers and most of the well-differentiated tumors are managed by general gynecologists and often without appropriate incision or surgical staging. Recently, two randomized multicenter studies reported no evidence of benefits in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with preoperative International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer (9, 10).

Most of the studies which have investigated preoperative tumor grading by various endometrial sampling methods have shown that these methods are poorly correlated with the final pathologic grade (8, 11-13). A higher FIGO grade on final uterine pathologic examination will be diagnosed in 24% of patients with preoperative FIGO grade 1 and the vast majority of cases will be upgraded to FIGO grade 2, but approximately 3% will be upgraded to FIGO grade 3 or be diagnosed as a serous or clear cell carcinoma on final pathologic assessment of the hysterectomy specimen (7-12). However, there are some studies that show nearly perfect agreement between preoperative and final pathologic grades (14, 15).

The objective of this study was to compare preoperative grading with the final pathological assessment of the hysterectomy specimen. The second objective of the study was to determine the high-risk group who will be upgraded in the postoperative evaluation.

Materials and Methods

Between June 2000 and January 2011, a total of 335 patients with endometrioid type endometrial cancer were evaluated retrospectively. These cases were identified from a database after approval was granted by the Institutional Review Board at the Bakirkoy Women’s and Children’s Teaching and Research Hospital and Haseki Teaching and Research Hospital. D&C was used as the method of endometrial sampling in all cases. All patients underwent hysterectomy and lymphadenectomy as the primary treatment for their endometrial cancer. All of the preoperative endometrial histological examinations were performed and reviewed at these two institutions by specialized gynecologic pathologists. Only the patients with preoperatively diagnosed endometrioid endometrial carcinoma were evaluated in this study. Cases of serous or clear cell adenocarcinoma, whether alone or mixed with the other subtypes and non-epithelial histology, were excluded.

Operative reports were reviewed to determine intraoperative findings. The pathology reports of the specimens revealed the FIGO grade, the depth of myometrial invasion, the FIGO stage of disease, the presence of extra-uterine metastases, the peritoneal cytologic results and the presence of lymphvascular space invasion (LVI). Patients were classified as upgraded if the postoperative definitive grade was determined to be a greater then the preoperative grade.

The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy rates were calculated for all preoperatively assessed grades. Chi-square and Fisher’s exact tests were used, as appropriate, to compare nominal variables. All statistical analyses were performed using SPSS for Windows version 15.0.1 (Chicago, IL).

Results

A total of 335 patients with endometrioid type endometrial cancer were evaluated. The mean age of the patients was 56.2±9.6 and the vast majority of the patients were postmenopausal (n=239, 71.3%). Table 1 summarizes the demographic and clinic characteristics of the patients. Most of the patients had grade 2 disease (n=152, 45.4%). 40.9% and 13.7% of them had grade 1 and grade 3 disease at the final pathologic examination, respectively.

Table 2 shows the distribution of the surgical outcomes according to the preoperative grades of the patients. FIGO grade was determined to be greater in 75 patients in the final hysterectomy specimen. Fifty-five (32.9%) of the patients with preoperative grade 1 were found to be grade 2 and 3.6% of them were

| Table 1. Demographic and clinical characteristics of the patients |
|-------------------------------|------------------|
| Age (mean±sd)                   | 56.2±9.6         |
| Gravida (median)                 | 3.0              |
| Parity (median)                  | 3.0              |
| Menopause                        | 239 (46.0)       |
| BMI ≥30                          | 182 (35.0)       |
| DM                               | 88 (16.9)        |
| HT                               | 142 (27.3)       |
| Operation                        |                  |
| TAH-BSO-PLND                     | 193 (55.7)       |
| TAH-BSO-PPLND                    | 142 (42.3)       |

BMI: body mass index, DM: diabetes mellitus, HT: hypertension, TAH-BSO-PLND: total abdominal hysterectomy-bilateral salpingoophorectomy-pelvic lymph node dissection, TAH-BSO-PPLND: total abdominal hysterectomy-bilateral salpingoophorectomy-pelvic and para-aortic lymph node dissection.
upgraded to grade 3. Fourteen of the patients with grade 2 (11.4%) were found to be grade 3. The vast majority of the patients with preoperative grade 1 had stage I disease (80.2%), 6.0% of them had stage II, 9.0% and 4.8% of the patients had stage III and IV disease. Lymph node involvement was detected in 11.4% and the depth of myometrial invasion (MI) was greater than 50% in 24.6% of the patients who had grade 1 tumors preoperatively.

The overall accuracy rate of preoperative histologic grade evaluation was 64.1%. The sensitivity, specificity, PPV and NPV rates of the preoperative grade prediction are summarized in Table 3. Among the preoperatively assessed grades, grade 1 had higher sensitivity (77.3%) and lower specificity rates (67.5%) compared with grade 2 and grade 3. The accuracy rates of the preoperative grade assessment with endometrial sampling were 75.5%, 66.2% and 88.3% for grades 1, 2 and 3, respectively. If the patients with a preoperative diagnosis of grade 3 were excluded, 25.8% of the patients were found to have a higher grade in the final pathologic examination. A comparison of the demographic and pathologic characteristics between patients with or without upgraded cancer is summarized in Table 4. Upgraded tumors were significantly related to a higher stage of disease (p=0.003) and positive peritoneal cytology (p=0.04).

Discussion

The surgical approach for endometrial cancer varies from only total hysterectomy with bilateral oophorectomy to hysterectomy with full pelvic and para-aortic lymphadenectomy. Preoperative tumor grading with pre- and/or intraoperative assessment of the depth of myometrial invasion, as well as the histologic subtype, is frequently used to decide whether lymph node dissection is necessary at the time of hysterectomy. According to FIGO guidelines, lymphadenectomy should be performed when myometrial invasion is greater than 50% and/or when the tumor is undifferentiated (16). Similarly, Mariani et al. (17) reported that patients with FIGO grade 1 or 2 endometrial cancer with macroscopically no or superficial myometrial invasion (<50%) can be treated safely with only hysterectomy. However, pre- and

### Table 2. Comparison of the surgical outcomes according to preoperative FIGO grade

| Preoperative Grade | Final Grade | Final FIGO stage | Postoperative Histology | Depth of MI |
|-------------------|-------------|------------------|-------------------------|-------------|
|                   | 1 (n)       | 2 (n)            | 3 (n)                  | <1/2        |
|                   | 106 (63.5)  | 28 (22.8)        | 3 (6.7)                | 126 (75.4)  |
|                   | 55 (32.9)   | 81 (65.9)        | 16 (35.6)              | 77 (62.6)   |
|                   | 6 (3.6)     | 14 (11.4)        | 26 (57.8)              | 46 (37.4)   |

|                  | 1 (n)       | 2 (n)            | 3 (n)                  | >1/2        |
|                  | 106 (63.5)  | 28 (22.8)        | 3 (6.7)                | 41 (24.6)   |
|                  | 55 (32.9)   | 81 (65.9)        | 16 (35.6)              | 46 (37.4)   |
|                  | 6 (3.6)     | 14 (11.4)        | 26 (57.8)              | 25 (35.6)   |

LNI: lymph node invasion, LVSI: lymphovascular space invasion, MI: myometrial invasion

### Table 3. Sensitivity, specificity, PPV and NPV for preoperative grade prediction

| Grade | Grade 1 | Grade 2 | Grade 3 |
|-------|---------|---------|---------|
| Sensitivity | 77.3% | 53.2% | 56.5% |
| Specificity | 67.5% | 77.0% | 93.4% |
| PPV | 63.4% | 65.8% | 57.7% |
| NPV | 80.3% | 66.5% | 93.1% |
| Accuracy | 75.5% | 66.2% | 88.3% |

PPV: positive predictive value, NPV: negative predictive value

with grade 2 and grade 3. The accuracy rates of the preoperative grade assessment with endometrial sampling were 75.5%, 66.2% and 88.3% for grades 1, 2 and 3, respectively.
intraoperative assessment of the myometrium is an inaccurate predictor of the actual depth of myometrial invasion (11). In a series of 112 patients, Frumovitz et al. (11) reported that a frozen section diagnosis of no myometrial invasion is not accurate in 72% of cases, and 26% of cases with a frozen section of myometrial invasion <50% will actually have deeper invasion, cervical invasion and/or extra-uterine disease.

Preoperative tumor grade based on endometrial sampling is also reported to be poorly correlated with the final pathologic grade (8, 11-13, 18, 19) and a greater FIGO grade on final hysterectomy pathological assessment will be diagnosed as high as in 30% of patients with preoperative FIGO grade 1 (12). In another study, which compared histological grades between D&C and the hysterectomy specimen in grade 1 tumors on the final hysterectomy pathological assessment showed an overall upgrade rate of 50% and a concordance rate of 32.5% (20).

On the other hand, Kang et al. (14) recently evaluated a total of 122 patients with low-risk endometrial cancer for the necessity of lymphadenectomy and showed nearly perfect agreement between pre- and postoperative grades, even when Pipelle was used for the preoperative diagnosis. Similarly, in a study with a very large series of only preoperatively detected as grade 1 endometrial cancer, almost 15% of the pathology specimens were upgraded in the final hysterectomy specimen (15).

In our study, nearly 35% of the patients with FIGO grade 1 endometrial adenocarcinoma prior to hysterectomy were diagnosed with a greater FIGO grade after hysterectomy. This finding may be explained by the fact that FIGO grading is based on the percentage of solid growth within a specimen and will therefore vary once the final specimen is obtained and a greater tissue volume is examined. In addition to this, 13.8% of the patients with preoperative grade 1 disease had advanced stage of disease (stage 3 and 4). Lymph node involvement was detected in 11.4% of the patients with preoperative grade 1 and 9% of them had positive peritoneal cytology. If the patients were selected for surgical staging according to preoperative grading, more than 10% of the patients with preoperative grade 1 would have been subjected to inappropriate surgery in our cohort.

In an Italian multicenter study which evaluated the efficacy of systemic lymphadenectomy in patients with preoperative and intraoperative stage 1 disease, almost 25% of the total cohort was upstaged (FIGO II, III, IV) after definitive surgery and a very large series of only preoperatively detected as grade 1 endometrial cancer, almost 15% of the pathology specimens were upgraded in the final hysterectomy specimen (15).

### Table 4. Univariate analysis for the patients with or without upgraded tumors

|                        | Upgraded n (%) | Not upgraded n (%) | p       |
|------------------------|----------------|--------------------|---------|
| Age (years)            |                |                    |         |
| <70                    | 72 (96.0)      | 200 (93.0)         | 0.35    |
| ≥70                    | 3 (4.0)        | 15 (7.0)           |         |
| Menopause status       |                |                    | 0.88    |
| Premenopausal          | 22 (29.3)      | 65 (30.2)          |         |
| Postmenopausal         | 53 (70.7)      | 150 (69.8)         |         |
| BMI                    |                |                    | 0.19    |
| <30                    | 39 (52.0)      | 93 (43.3)          |         |
| ≥30                    | 36 (48.0)      | 122 (56.7)         |         |
| DM                     |                |                    | 0.23    |
| 15 (20.0)              | 58 (27.0)      | 0.22               |
| HT                     |                |                    |         |
| 36 (48.0)              | 86 (40.0)      | 0.003*             |
| Final FIGO stage       |                |                    |         |
| I                      | 46 (61.3)      | 204 (78.4)         |         |
| II                     | 9 (12.0)       | 16 (6.2)           |         |
| III                    | 10 (13.3)      | 26 (10.0)          |         |
| IV                     | 10 (12.3)      | 14 (5.4)           |         |
| LNI                    |                |                    | 0.07    |
| 59 (78.7)              | 226 (86.9)     | 0.04               |
| Positive Cytology      |                |                    |         |
| 14 (18.7)              | 26 (10.0)      | 0.32               |
| LVS1                   |                |                    |         |
| 23 (30.7)              | 65 (27.0)      | 0.59               |
| Depth of MI            |                |                    |         |
| <1/2                   | 48 (64.0)      | 175 (67.3)         |         |
| >1/2                   | 27 (36.0)      | 85 (32.7)          |         |

BMI: body mass index, DM: diabetes mellitus, HT: hypertension, LNI: lymph node invasion, LVS1: lymphovascular space invasion, MI: myometrial invasion

*X2* test for trend
patients undergoing systemic lymphadenectomy had a higher likelihood of being upstaged to FIGO IIIC disease compared the no lymphadenectomy arm (13.3% vs. 3.2%) (10). Another randomized trial (MRC ASTEC) also showed that 23% of patients with a preoperatively diagnosed stage I tumor were upstaged in both the standard surgery and lymphadenectomy arms (11). Our second objective in conducting this study was to preoperatively determine the high risk group in which patients will be upgraded in postoperative evaluation. However, there was no statistically significant difference in the demographic and clinical features between patients with or without upgraded tumors. We found a significant relation only between the stage of disease, positive abdominal cytology and upgrading. However, those were mostly detected after surgical staging. Thus, it is not possible to predict the high risk group for upgrading preoperatively findings.

In conclusion, unpredictably, a high percentage of preoperatively diagnosed as grade 1 tumors were upgraded in the postoperative evaluation. According to our study, it is not possible to say that lymphadenectomy should be considered as comprehensive surgical staging in all patients with preoperatively diagnosed endometrial cancer, but it should be mentioned that patients with a preoperative diagnosis of grade 1 uterine cancers have a risk of extra-uterine spread, and the information achieved from an appropriate surgical staging procedure affects the adjuvant treatment decision.

Conflict of interest
No conflict of interest was declared by the authors.

References
1. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer 1987; 60: 2035-41. [CrossRef]
2. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway: a study of a total population. Cancer 1991; 67: 3093-103. [CrossRef]
3. Announcement. FIGO stages: 1988 revisions. Gynecol Oncol 1989; 35: 125-7. [CrossRef]
4. American College of Obstetricians and Gynecologists.ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer.Obstet Gynecol Oncol 2005; 106: 413-25.
5. Barnes NM, Kíljøre LC. Complete surgical staging of early endometrial adenocarcinoma. Optimizing patients outcomes. Semin Radiat Oncol 2000; 10: 3-7. [CrossRef]
6. Geisler JP, Wiedeman MC, Zhou Z, Miller GA, Geisler HE. Using FIGO histologic grade to determine when to perform lymphadenectomies in endometrioid adenocarcinoma of the endometrium. Eur J Gynaecol Oncol 1996; 17: 204-7.
7. Orr Jr JW, Roland PY, Leichter D, Orr PF. Endometrial cancer: is surgical staging necessary? Curr Opin Oncol 2001; 13: 408-12. [CrossRef]
8. Ben-Shachar I, Pavelka J, Cohn DE, Copeland LJ, Ramirez N, Manolitsa T, et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005; 105: 487-93. [CrossRef]
9. ASTEC study group, Kitchener H, Swart AM, Qian Q, Anjos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373: 125-36. [CrossRef]
10. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial cancer: randomized clinical trial. J Natl Cancer Inst 2008; 100: 1707-16. [CrossRef]
11. Frumovitz M, Singh DK, Meyer L, Smith DH, Wetheim I, Resnek E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004; 95: 463-8. [CrossRef]
12. Eltabbakh GH, Shamoun J, Mount SL. Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol 2005; 99: 309-12. [CrossRef]
13. Case AS, Rocconi RP, Straugh Jr JM, Conner M, Novak L, Wang W, et al. A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol 2006; 108: 1375-9. [CrossRef]
14. Kang WD, Kim CH, Cho MK, Kim JW, Kim YH, Choi HS, et al. Lymphadenectomy for low-risk endometrial cancer based on preoperative and intraoperative assessments. Int J Gynecol Cancer. 2009; 19: 657-61. [CrossRef]
15. Leitao MM, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbiti C, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma Gynecol Oncol 2009; 113: 105-8. [CrossRef]
16. Benedetti JL, Bender H, Jones H 3rd, Ngn HY, Pecorelli S. FIGO staging classifications and clinical practices guidelines in management of gynecologic cancers. Int J Gynecol Obstet 2000; 70: 209-62. [CrossRef]
17. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000; 182: 1506-19. [CrossRef]
18. Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995; 86: 38-42. [CrossRef]
19. Obermair A, Geranou M, Gucer F, Denison U, Graf AH, Kapshammer E, et al. Endometrial cancer: accuracy of the finding of a well-differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer 1999; 9: 383-6. [CrossRef]
20. Wang X, Zhang H, Di W, Li W. Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimen for histologic grade and depth of myometrial invasion in endometrial carcinoma. Am J Obstet Gynecol 2009; 201: 194. e1-e10.